Seino M, Abe K, Nushiro N, Omata K, Kasai Y, Yoshinaga K
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
J Hypertens Suppl. 1988 Dec;6(4):S401-3. doi: 10.1097/00004872-198812040-00126.
We used a newly synthesized competitive antagonist of bradykinin (B 4147) to determine whether bradykinin contributes to the maintenance of blood pressure and renal blood flow in anaesthetized Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). The injection of B 4147 (50 micrograms, intravenously) caused an increase in blood pressure and a decrease in renal blood flow in both strains. However, the magnitude in the change in blood pressure was significantly lower in SHR than in WKY. The reduction of renal blood flow was greater in WKY than in SHR, but there was no significant difference in the basal renal blood flow. These results indicate that bradykinin contributes to the maintenance of blood pressure and renal blood flow in both strains. However, bradykinin antagonist produced a more prominent systemic effect in WKY than in SHR. This suggests that a deficiency in the bradykinin system in SHR contributes to the development or the maintenance of hypertension.
我们使用一种新合成的缓激肽竞争性拮抗剂(B 4147)来确定缓激肽是否有助于维持麻醉的Wistar-Kyoto大鼠(WKY)和自发性高血压大鼠(SHR)的血压及肾血流量。静脉注射B 4147(50微克)导致两种品系的血压升高和肾血流量减少。然而,SHR血压变化的幅度显著低于WKY。WKY肾血流量的减少幅度大于SHR,但基础肾血流量无显著差异。这些结果表明,缓激肽有助于维持两种品系的血压和肾血流量。然而,缓激肽拮抗剂在WKY中产生的全身效应比在SHR中更显著。这表明SHR中缓激肽系统的缺陷有助于高血压的发生或维持。